Literature DB >> 17076994

Pramlintide: A new tool in diabetes management.

Laura L Want, Robert E Ratner.   

Abstract

The amylin analogue pramlintide acts in concert with insulin to regulate glucose metabolism. It reduces postprandial hyperglycemia by suppressing postprandial glucagon secretion, regulating gastric emptying, and reducing food intake. In clinical use, pramlintide reduces postprandial glycemic excursions and improves A(1c) without the weight gain and increased risk of hypoglycemia typically seen with intensification of diabetes therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17076994     DOI： 10.1007/s11892-006-0004-0

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


  15 in total

1.  A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

Authors:  Fred Whitehouse; Davida F Kruger; Mark Fineman; Larry Shen; James A Ruggles; David G Maggs; Christian Weyer; Orville G Kolterman
Journal:  Diabetes Care       Date:  2002-04       Impact factor: 19.112

2.  Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

Authors:  Claresa Levetan; Laura L Want; Christian Weyer; Susan A Strobel; John Crean; Yan Wang; David G Maggs; Orville G Kolterman; Manju Chandran; Sunder R Mudaliar; Robert R Henry
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

3.  Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.

Authors:  Antonio Ceriello; Ludovica Piconi; Lisa Quagliaro; Yan Wang; Catherine A Schnabel; James A Ruggles; Maurice A Gloster; David G Maggs; Christian Weyer
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

4.  Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus.

Authors:  E Schvarcz; M Palmér; J Aman; M Horowitz; M Stridsberg; C Berne
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

Review 5.  Amylin, food intake, and obesity.

Authors:  Tarek K Reda; Allan Geliebter; F Xavier Pi-Sunyer
Journal:  Obes Res       Date:  2002-10

Review 6.  Relationships of upper gastrointestinal motor and sensory function with glycemic control.

Authors:  C K Rayner; M Samsom; K L Jones; M Horowitz
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

7.  Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Authors:  R E Ratner; R Dickey; M Fineman; D G Maggs; L Shen; S A Strobel; C Weyer; O G Kolterman
Journal:  Diabet Med       Date:  2004-11       Impact factor: 4.359

8.  Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Authors:  Priscilla A Hollander; Philip Levy; Mark S Fineman; David G Maggs; Larry Z Shen; Susan A Strobel; Christian Weyer; Orville G Kolterman
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

9.  Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

Authors:  David G Maggs; Mark Fineman; Jonathan Kornstein; Terrie Burrell; Sherwyn Schwartz; Yan Wang; James A Ruggles; Orville G Kolterman; Christian Weyer
Journal:  Diabetes Metab Res Rev       Date:  2004 Jan-Feb       Impact factor: 4.876

10.  U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.

Authors: 
Journal:  Diabetes       Date:  1995-11       Impact factor: 9.461
View more
  2 in total

1.  Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.

Authors:  Boris P Kovatchev; John Crean; Anthony McCall
Journal:  Diabetes Technol Ther       Date:  2008-10       Impact factor: 6.118

Review 2.  Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk.

Authors:  Byron J Hoogwerf; Krupa B Doshi; Dima Diab
Journal:  Vasc Health Risk Manag       Date:  2008
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.